Suppr超能文献

新型冠状病毒肺炎合并呼吸机相关性肺炎患者的预后因素:单中心经验

Prognostic Factors in COVID-19 Patients with Ventilator-Associated Pneumonia: A Single-Centre Experience.

作者信息

Ekici Hilal, Zor-Çakıllı Seda, Arman-Fırat Emine, Eryılmaz-Eren Esma, Çelik İlhami

机构信息

Infectious Diseases and Clinical Microbiology Clinic, Yozgat City Hospital, Yozgat, Türkiye.

Infectious Diseases and Clinical Microbiology Clinic, Adıyaman Besni State Hospital, Adıyaman, Türkiye.

出版信息

Infect Dis Clin Microbiol. 2025 Jun 26;7(2):143-155. doi: 10.36519/idcm.2025.522. eCollection 2025 Jun.

Abstract

OBJECTIVE

Coronavirus disease 2019 (COVID-19) presents with a broad range of symptoms, varying from mild or moderate illness to severe cases such as acute respiratory distress syndrome (ARDS) and death.  This study aimed to identify risk factors associated with the development of ventilator-associated pneumonia (VAP) and its impact on 14-day mortality in mechanically ventilated COVID-19 patients.

MATERIALS AND METHODS

This study was conducted in our hospital's intensive care units (ICUs) between July 2020 and July 2021. It included patients aged 18 years and older who tested positive for SARS-CoV-2 by PCR. Demographic data, comorbidities, immunosuppressive treatments, antimicrobial therapies, and laboratory values were evaluated, along with pathogen identification and antimicrobial resistance rates.

RESULTS

A total of 311 patients were included in the study. The mean age was 72.6 ± 11.9 years. Hypertension (48.6%) was the most frequent comorbidity. Among patients who survived on day 14, higher rates of methylprednisolone (MP) use were observed (=0.019), along with longer duration (<0.001) and greater total dose (<0.001). Pulse steroid therapy was more common in survivors (28%, =0.007). Among patients who developed VAP, the duration and total dose of MP were higher (<0.001 for both). Antibiotic therapy on day 14 showed macrolides (59.6%) and third-generation cephalosporins (36.5%) as the most frequently used. was the most commonly isolated pathogen (62.5%), with 100% resistance to third-generation cephalosporins in strains and 83.3% in . All strains of , , and were resistant to carbapenems.

CONCLUSION

Fourteen-day survival was associated with higher corticosteroid use, including dexamethasone and MP, along with pulse steroid therapy. The use of immunosuppressive agents was more common in patients who developed VAP. Given the potential link between immunosuppressive therapy and VAP development, tailored treatment strategies should be considered for these patients.

摘要

目的

2019冠状病毒病(COVID-19)症状表现广泛,从轻症或中症到重症,如急性呼吸窘迫综合征(ARDS)甚至死亡。本研究旨在确定与机械通气的COVID-19患者发生呼吸机相关性肺炎(VAP)相关的危险因素及其对14天死亡率的影响。

材料与方法

本研究于2020年7月至2021年7月在我院重症监护病房(ICU)进行。纳入年龄18岁及以上经PCR检测SARS-CoV-2呈阳性的患者。评估人口统计学数据、合并症、免疫抑制治疗、抗菌治疗及实验室检查结果,以及病原体鉴定和抗菌药物耐药率。

结果

本研究共纳入311例患者。平均年龄为72.6±11.9岁。高血压(48.6%)是最常见的合并症。在第14天存活的患者中,观察到甲泼尼龙(MP)使用比例更高(=0.019),使用持续时间更长(<0.001)且总剂量更大(<0.001)。脉冲类固醇疗法在存活者中更常见(28%,=0.007)。在发生VAP的患者中,MP的使用持续时间和总剂量更高(两者均<0.001)。第14天的抗生素治疗显示,大环内酯类(59.6%)和第三代头孢菌素(36.5%)是最常用的药物。是最常分离出的病原体(62.5%),菌株对第三代头孢菌素的耐药率为100%,菌株为83.3%。所有、和菌株对碳青霉烯类均耐药。

结论

14天生存率与包括地塞米松和MP在内的更高剂量皮质类固醇使用以及脉冲类固醇疗法相关。免疫抑制剂的使用在发生VAP的患者中更为常见。鉴于免疫抑制治疗与VAP发生之间的潜在联系,应考虑为这些患者制定个性化的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25fb/12255315/db3cad35ebb2/IDCM-2025-522-Figure-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验